The Phase II trial will assess the therapy’s safety, tolerability and its activity across various biomarkers in IPF patients.

Researchers have identified a potential new way to treat idiopathic pulmonary fibrosis (IPF), a deadly and currently incurable lung disease that affects more than 3 million people worldwide.